Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
about
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best PracticeA systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney diseaseAutosomal dominant polycystic kidney disease: recent advances in clinical managementIdentification of people with autosomal dominant polycystic kidney disease using routine data: a cross sectional study.Translational nephrology: what translational research is and a bird's-eye view on translational research in nephrologyBlood pressure in early autosomal dominant polycystic kidney disease.Lack of Benefit of Early Intervention with Dietary Flax and Fish Oil and Soy Protein in Orthologous Rodent Models of Human Hereditary Polycystic Kidney DiseaseAnthropometric and Metabolic Risk Factors for ESRD Are Disease-Specific: Results from a Large Population-Based Cohort Study in Austria.Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.Renal volume and cardiovascular risk assessment in normotensive autosomal dominant polycystic kidney disease patientsClinical Manifestation and Management of ADPKD in Western Countries.Effect of renal transcatheter arterial embolization on quality of life in patients with autosomal dominant polycystic kidney disease.European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.Metabolomic Alterations Associated with Cause of CKD.Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease.The prevalence of autosomal dominant polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition.A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model.Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan.Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.Polycystic kidney disease: Tolvaptan slows disease progression in late-stage ADPKD.Case report: a thiazide diuretic to treat polyuria induced by tolvaptan.End-Stage Kidney Disease in Patients With Autosomal Dominant Polycystic Kidney Disease: A 12-Year Study Based on the Canadian Organ Replacement Registry.
P2860
Q26767011-1B140BF9-E0A0-402D-A0E2-09ED0B694325Q26798115-8A8C92B6-21DD-470B-A69A-CD1D920F4FF8Q28079782-86B12CC8-C73E-4B61-A016-7E7EBCC7EEFBQ30870783-F8F40B30-8410-4972-A507-85EC44F4D5BDQ35026517-2CED14BD-83D4-4D3F-B63A-BFC4BF58C469Q35129320-7F1DDF7D-115F-4798-A8D5-5AD5A2BD8471Q36026246-D2D4F2E8-5D85-4FB3-9564-02D9063D6922Q36106884-F61A34F5-D82C-42A5-82D4-8DA0BFDA3B22Q36753925-6437592F-7120-4DB4-BC2A-17D4EA762A93Q37606169-FF11A5C6-35EE-4BAC-8DED-42E37A025468Q39030254-B1CD52DC-4866-49D3-8ED6-B949DE256701Q40040634-7C448416-0C46-4119-A411-D237CB463A6BQ47564027-9FBA4D1D-8ABA-4B22-BA5F-65ACCF12C4CCQ47710032-EFF26FC7-E6DD-4968-BCC3-66ECF6DE7438Q47831593-92602D11-09A4-46A9-9624-F87D79B129E9Q48235375-9AC65B43-98BD-4F70-B514-022AE0FB1C35Q49198447-2F5EB573-1C84-4E9B-9BB8-6DC762EC9B31Q49769689-10A4ED5A-AD33-4DE6-91D7-990BF14E8E21Q49855458-EE367C49-B080-4294-94C0-6358F9C8F4FEQ54293523-0FBCF71F-6FAC-4606-A95F-569B9315DEE4Q55501159-28943C48-94B2-4240-BF41-734980F589BEQ55515028-F805B17C-B673-44C4-9EF9-C87C6513C3F0
P2860
Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@ast
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@en
type
label
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@ast
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@en
prefLabel
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@ast
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@en
P2093
P356
P1433
P1476
Analysis of data from the ERA- ...... ant polycystic kidney disease.
@en
P2093
Andries Hoitsma
Anneke Kramer
Bjarne Orskov
Christoph Wanner
Damian G Fogarty
ERA-EDTA Registry
Edwin M Spithoven
Esther Meijer
EuroCYST Consortium
Fergus Caskey
P2888
P304
P356
10.1038/KI.2014.120
P407
P577
2014-05-14T00:00:00Z
P6179
1015069718